Free Trial
NASDAQ:PHVS

Pharvaris Q2 2023 Earnings Report

Pharvaris logo
$16.39 -0.01 (-0.06%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$16.38 -0.02 (-0.09%)
As of 05/22/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris EPS Results

Actual EPS
-$0.69
Consensus EPS
-$0.71
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 7, 2023
Conference Call Time
7:00AM ET

Earnings Documents

Pharvaris Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Wedbush Issues Optimistic Forecast for Pharvaris Earnings
What is Leerink Partnrs' Estimate for Pharvaris Q2 Earnings?
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

View Pharvaris Profile

More Earnings Resources from MarketBeat